263 related articles for article (PubMed ID: 31233775)
1. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
[TBL] [Abstract][Full Text] [Related]
2. Hepatic-Targeted Nano-enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis.
Tong Y; Yu X; Huang Y; Zhang Z; Mi L; Bao Z
ChemMedChem; 2023 Mar; 18(5):e202200468. PubMed ID: 36380399
[TBL] [Abstract][Full Text] [Related]
3. Hepatic parenchymal cell and mitochondrial-targeted astaxanthin nanocarriers for relief of high fat diet-induced nonalcoholic fatty liver disease.
Che T; Song Y; Su W; Xing S; Wang H; Tan M
Food Funct; 2023 Mar; 14(6):2908-2920. PubMed ID: 36883333
[TBL] [Abstract][Full Text] [Related]
4. Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease.
Fan N; Zhao J; Zhao W; Zhang X; Song Q; Shen Y; Shum HC; Wang Y; Rong J
J Control Release; 2022 Jul; 347():44-54. PubMed ID: 35483638
[TBL] [Abstract][Full Text] [Related]
5. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
6. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
7. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
[TBL] [Abstract][Full Text] [Related]
8. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
9. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway.
Wang ZQ; Zhang XH; Yu Y; Tipton RC; Raskin I; Ribnicky D; Johnson W; Cefalu WT
Metabolism; 2013 Sep; 62(9):1239-49. PubMed ID: 23702383
[TBL] [Abstract][Full Text] [Related]
10. Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease.
Li X; Chen XX; Xu Y; Xu XB; Wu WF; Zhao Q; Hu JN
Biomacromolecules; 2022 Jan; 23(1):409-423. PubMed ID: 34964604
[TBL] [Abstract][Full Text] [Related]
11. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
12. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c.
Wang L; Zhu X; Sun X; Yang X; Chang X; Xia M; Lu Y; Xia P; Yan H; Bian H; Gao X
Lipids Health Dis; 2019 Nov; 18(1):197. PubMed ID: 31729980
[TBL] [Abstract][Full Text] [Related]
13. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
14. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
15. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
16. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
17. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
18. Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis.
Dogra S; Kar AK; Girdhar K; Daniel PV; Chatterjee S; Choubey A; Ghosh S; Patnaik S; Ghosh D; Mondal P
Nanomedicine; 2019 Apr; 17():210-222. PubMed ID: 30708053
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
Li J; Xie S; Teng W
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010950
[TBL] [Abstract][Full Text] [Related]
20. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
